Anti-TROP2 (Sacituzumab Govitecan), Humanized Antibody
Catalogue number:
A2175-100
Supplier:
BioVision
Size:
100 µg _$$_
Product is available in:
N/A
Shipping is calculated in checkout
This product is no longer available to order.
Antibody Host:
Recombinant
Species Reactivity:
Human
Antibody Isotype:
IgG1, kappa
Antibody Type:
Monoclonal
Immunogen:
Human TROP2
- Data sheet: View or download
Product Description:
The research-grade biosimilar is an antibody-drug conjugate that targets TROP-2 that is expressed on cancer cells. The original conjugate consists of an anti-TROP2 humanized monoclonal antibody (RS7-3G11) that is chemically linked to a cytotoxic drug SN-38 via a hydrolyzable CL2A linker. Upon internalization in the cell, the SN-38 is released from the antibody via the hydrolysis of the CL2A linker. SN-38 inhibits DNA topoisomerase I and induces DNA-damage mediated cell death. The original antibody-drug conjugate received approval from the FDA in 2020 to treat patients with metastatic triple-negative breast cancer who have received at least two prior treatment regimens
Storage Temperature:
-80°C